Please assess the completion status of the following clinical trial:

Trial Title: Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GA \< 26 weeks~* Maternal age \> 18 years of age~* Singleton pregnancy~* Normal chromosomes~* CCAM volume to head circumference ratio (CVR) \> 1.4~* No maternal medical/surgical contraindications~* No evidence of hydrops~* Not previously randomization~Exclusion Criteria:~* Maternal diabetes or use of insulin~* Preterm labor~* Multiple congenital anomalies with CCAM~* Chromosomal anomaly with CCAM~* Multiple gestation pregnancy with CCAM~* Not willing to be randomized~* Unable or unwilling to return to UCSF for second dose of drug or placebo~* CVR \< 1.4

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active Study Group (Type: ACTIVE_COMPARATOR): STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
- Placebo Group (Type: PLACEBO_COMPARATOR): PLACEBO: IM x 2 doses 24 hours apart

Based on this trial design, predict the completion outcome and termination type (if applicable).